121
Views
5
CrossRef citations to date
0
Altmetric
Review

Prognostic Factors and Clinical Considerations for Iron Chelation Therapy in Myelodysplastic Syndrome Patients

&
Pages 1019-1030 | Published online: 03 Dec 2021

References

  • Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes [erratum appears in Blood 91:1100, 1998]. Blood. 1997;89:2079–2088. doi:10.1182/blood.V89.6.2079
  • Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–2456. doi:10.1182/blood-2012-03-420489
  • Leitch HA, Buckstein R, Zhu N, et al. Iron overload in myelodysplastic syndromes: evidence based guidelines from the Canadian consortium on MDS. Leuk Res. 2018;74:21–41. doi:10.1016/j.leukres.2018.09.005
  • Angelucci E, Li J, Greenberg P, et al. Iron chelation in transfusion-dependent patients with low- to intermediate-1–risk myelodysplastic syndromes. Ann Intern Med. 2020;172(8):513–522. doi:10.7326/M19-0916
  • Santini V, Alessandrino PE, Angelucci E, et al. Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leuk Res. 2010;34:1576–1588. doi:10.1016/j.leukres.2010.01.018
  • Musto P, Maurillo L, Simeon V, et al. Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study. Br J Haematol. 2017;177:741–750. doi:10.1111/bjh.14621
  • Fenaux P, Rose C. Impact of iron overload in myelodysplastic syndromes. Blood Rev. 2009;23(Suppl 1):S15–19. doi:10.1016/S0268-960X(09)70005-0
  • Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23:7594–7603. doi:10.1200/JCO.2005.01.7038
  • Cortelezzi A, Cattaneo C, Cristiani S, et al. Nontransferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis? Hematol J. 2000;1:153–158. doi:10.1038/sj.thj.6200028
  • Santini V, Girelli D, Sanna A, et al. Hepcidin levels and their determinants in different types of myelodysplastic syndromes. PLoS One. 2011;6:e23109. doi:10.1371/journal.pone.0023109
  • Ganz T, Nemeth E. Hepcidin and disorders of iron metabolism. Annu Rev Med. 2011;62:347–360. doi:10.1146/annurev-med-050109-142444
  • Pullarkat V. Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye? Blood. 2009;114:5251–5255. doi:10.1182/blood-2009-07-234062
  • Donovan A, Lima CA, Pinkus JL, et al. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab. 2005;1:191–200. doi:10.1016/j.cmet.2005.01.003
  • Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306:2090–2093. doi:10.1126/science.1104742
  • Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of Mammalian iron metabolism. Cell. 2010;142:24–38. doi:10.1016/j.cell.2010.06.028
  • Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med. 2007;13:1096–1101. doi:10.1038/nm1629
  • Tanno T, Noel P, Miller JL. Growth differentiation factor 15 in erythroid health and disease. Curr Opin Hematol. 2010;17:184–190. doi:10.1097/MOH.0b013e328337b52f
  • Kroot JJ, Kemna EH, Bansal SS, et al. Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization. Haematologica. 2009;94:1748–1752. doi:10.3324/haematol.2009.010322
  • Castagna A, Campostrini N, Zaninotto F, Girelli D. Hepcidin assay in serum by SELDI-TOF-MS and other approaches. J Proteomics. 2010;73:527–536. doi:10.1016/j.jprot.2009.08.003
  • Winder A, Lefkowitz R, Ghoti H, et al. Urinary hepcidin excretion in patients with myelodysplastic syndrome and myelofibrosis. Br J Haematol. 2008;142:669–671. doi:10.1111/j.1365-2141.2008.07225.x
  • Murphy PT, Mitra S, Gleeson M, Desmond R, Swinkels DW. Urinary hepcidin excretion in patients with low grade myelodysplastic syndrome. Br J Haematol. 2009;144:451–452. doi:10.1111/j.1365-2141.2008.07455.x
  • Cui R, Gale RP, Zhu G, et al. Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions. Leuk Res. 2014;38:545–550. doi:10.1016/j.leukres.2014.01.016
  • Bondu S, Alary A-S, Lefèvre C, et al. A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome. Sci Transl Med. 2019;11:eaav5467. doi:10.1126/scitranslmed.aav5467
  • Zhu Y, Li X, Chang C, et al. SF3B1-mutated myelodysplastic syndrome with ring sideroblasts harbors more severe iron overload and corresponding over-erythropoiesis. Leuk Res. 2016;44:8–16. doi:10.1016/j.leukres.2016.02.011
  • Shenoy N, Vallumsetla N, Rachmilewitz E, et al. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome. Blood. 2014;124:873–881. doi:10.1182/blood-2014-03-563221
  • Vinchi F, Hell S, Platzbecker U. Controversies on the consequences of iron overload and chelation in MDS. Hemasphere. 2020;4(3):e357. doi:10.1097/HS90000000000000357
  • Jin S, Su H, Tran NT, et al. Splicing factor SF3B1K700E mutant dysregulates erythroid differentiation via aberrant alternative splicing of transcription factor TAL1. PLoS One. 2017;12:e0175523. doi:10.1371/journal.pone.0175523
  • Dolatshad H, Pellagatti A, Fernandez-Mercado M, et al. Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells. Leukemia. 2015;29:1092–1103. doi:10.1038/leu.2014.331
  • Visconte V, Avishai N, Mahfouz R, et al. Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron. Leukemia. 2015;29:188–195. doi:10.1038/leu.2014.170
  • Inokura K, Fujiwara T, Saito K, et al. Impact of TET2 deficiency on iron metabolism in erythroblasts. Exp Hematol. 2017;49:56–67 e5. doi:10.1016/j.exphem.2017.01.002
  • Fabiani E, Valentini L, Cilloni D, Voso MT. Could haemochromatosis (HFE) gene mutations affect response to iron chelation in myelodysplastic syndrome? - Response to Lucijanic and Kusec. Br J Haematol. 2019;186(4):639–640. doi:10.1111/bjh.15938
  • Della Porta MG, Kuendgen A, Malcovati L, et al. Myelodysplastic syndrome (MDS)-specific comorbidity index for predicting the impact of extra-hematological comorbidities on survival of patients with MDS. Blood. 2008;112:11. doi:10.1182/blood-2008-02-078170
  • Brunner AM, Blonquist TM, Hobbs GS, et al. Risk and timing of cardiovascular death among patients with myelodysplastic syndromes. Blood Adv. 2017;1:2032–2040. doi:10.1182/bloodadvances.2017010165
  • Pascal L, Beyne-Rauzy O, Brechignac S, et al. Cardiac iron overload assessed by T2* magnetic resonance imaging and cardiac function in regularly transfused myelodysplastic syndrome patients. Br J Haematol. 2013;162:413–415. doi:10.1111/bjh.12368
  • Fuster JJ, MacLauchlan S, Zuriaga MA, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science. 2017;355:842–847. doi:10.1126/science.aag1381
  • Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488–2498. doi:10.1056/NEJMoa1408617
  • Swirski FK. From clonal haematopoiesis to the CANTOS trial. Nat Rev Cardiol. 2018;15:79–80. doi:10.1038/nrcardio.2017.208
  • Vinchi F, Porto G, Simmelbauer A, et al. Atherosclerosis is aggravated by iron overload and ameliorated by dietary and pharmacological iron restriction. Eur Heart J. 2019:1–16. doi:10.1093/eurheartj/ehy883
  • Xu S. Iron and atherosclerosis: the link revisited. Trends Mol Med. 2019;25:659–661. doi:10.1016/j.molmed.2019.05.012
  • Vinchi F, Muckenthaler MU, Da Silva MC, et al. Atherogenesis and iron: from epidemiology to cellular level. Front Pharmacol. 2014;5:1–20.3. doi:10.3389/fphar.2014.00094
  • Vinchi F, Simmelbauer A, Altamura S, et al. Iron accelerates cardiovascular disease: the importance of maintaining iron balance. Atherosclerosis. 2016;252:E241–E242. doi:10.1016/j.atherosclerosis.2016.07.030
  • Vinchi F. Non-transferrin-bound iron in the spotlight: novel mechanistic insights into the vasculotoxic and atherosclerotic effect of iron. Antioxid Redox Signal. 2021;35(6):387–414. doi:10.1089/ars.2020.8167
  • Wong CAC, Leitch HA. Delayed time from RBC transfusion dependence to first cardiac event in lower IPSS risk MDS patients receiving iron chelation therapy. Leuk Res. 2019;83:106170. doi:10.1016/j.leukres.2019.106170
  • Telfer PT, Prestcott E, Holden S, et al. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol. 2000;110:971–977. doi:10.1046/j.1365-2141.2000.02298.x
  • Milic S, Mikolasevic I, Orlic L, et al. The role of iron and iron overload in chronic liver disease. Med Sci Monit. 2016;22:2144–2151. doi:10.12659/MSM.896494
  • Neukirchen J, Fox F, Kündgen A, et al. Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of188 patients from the Düsseldorf MDS registry. Leuk Res. 2012;36:1067–1070. doi:10.1016/j.leukres.2012.04.006
  • Metzgeroth G, Dinter D, Schultheis B, et al. Deferasirox in MDS patients with transfusion-caused iron overload—a phase-II study. Ann Hematol. 2009;88:301–310. doi:10.1007/s00277-008-0588-3
  • Girmenia C, Candoni A, Delia M, et al. Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: expert panel consensus-based recommendations. Blood Rev. 2019;34:16–25. doi:10.1016/j.blre.2018.10.002
  • Ganz T. Iron and infection. Int J Hematol. 2018;107:7–15. doi:10.1007/s12185-017-2366-2
  • Wong CAC, Wong SAY, Leitch HA. Iron overload in lower international prognostic scoring system risk patients with myelodysplastic syndrome receiving red blood cell transfusions: relation to infections and possible benefit of iron chelation therapy. Leuk Res. 2018;67:75–81. doi:10.1016/j.leukres.2018.02.005
  • Kontoghiorghes GJ, Kolnagou A, Skiada A, et al. The role of iron and chelators on infections in iron overload and non iron loaded conditions: prospects for the design of new antimicrobial therapies. Hemoglobin. 2010;34:227–239. doi:10.3109/03630269.2010.483662
  • Thompson MG, Corey BW, Si Y, et al. Antibacterial activities of iron chelators against common nosocomial pathogens. Antimicrob Agents Chemother. 2012;56:5419–5421. doi:10.1128/AAC.01197-12
  • Neupane GP, Kim DM. In vitro time-kill activities of ciprofloxacinalone and in combination with the iron chelator deferasirox against Vibrio vulnificus. Eur J Clin Microbiol Infect Dis. 2010;29:407–410. doi:10.1007/s10096-010-0875-5
  • Lyons RM, Marek BJ, Paley C, et al. Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: registry analysis at 5 years. Leuk Res. 2017;56:88–95. doi:10.1016/j.leukres.2017.01.033
  • Leitch HA. Optimizing therapy for iron overload in the myelodysplastic syndromes. Drugs. 2011;71:155–177. doi:10.2165/11585280-000000000-00000
  • Angelucci E, Pilo F. Iron chelation therapy in MDS – the final answer. Clin Lymphoma Myeloma. 2019;19(S1):S75–S76. doi:10.1016/j.clml.2019.07.425
  • Pilo F, Angelucci E. A storm in the niche: iron, oxidative stress and haemopoiesis. Blood Rev. 2018;32:29–35. doi:10.1016/j.blre.2017.08.005
  • Porter JB, El-Alfy M, Viprakasit V, et al. Utility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers different underlying anemias before and after deferasirox treatment. Eur J Haematol. 2016;96(1):19–26. doi:10.1111/ejh.12540
  • Greenberg PL, Stone RM, Al-Kali A, et al. Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15:60–87. doi:10.6004/jnccn.2017.0007
  • Malcovati L, Hellstrom-Lindberg E, Bowen D, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013;122:2943–2964. doi:10.1182/blood-2013-03-492884
  • Bennett JM; Working Group on Transfusional Iron Overload. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol. 2008;83:858–861. doi:10.1002/ajh.21269
  • Mainous AG, Tanner RJ, Hulihan MM, et al. The impact of chelation therapy on survival in transfusional iron overload: a meta-analysis of myelodysplastic syndrome. Br J Haematol. 2014;167:720–723. doi:10.1111/bjh.13053
  • Zeidan AM, Griffiths EA. To chelate or not to chelate in MDS: that is the question! Blood Rev. 2018;32:368–377. doi:10.1016/j.blre.2018.03.002
  • Goldberg SL, Chen E, Corral M, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol. 2010;28:2847–2852. doi:10.1200/JCO.2009.25.2395
  • Rose C, Brechignac S, Vassilief D, et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myelodysplasies). Leuk Res. 2010;34:864–870. doi:10.1016/j.leukres.2009.12.004
  • Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, Phase III study. Lancet Oncol. 2009;10:223–232. doi:10.1016/S1470-2045(09)70003-8
  • Goncalves AC, Cortesao E, Oliveiros B, et al. Oxidative stress levels are correlated with P15 and P16 gene promoter methylation in myelodysplastic syndrome patients. Clin Exp Med. 2016;16:333–343. doi:10.1007/s10238-015-0357-2
  • Platzbecker U, Bornhäuser M, Germing U, et al. Red blood cell transfusion-dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndromes (MDS). Biol Blood Marrow Transplant. 2008;14:1217–1225. doi:10.1016/j.bbmt.2008.08.006
  • Alessandrino EP, Della Porta MG, Bacigalupo A, et al. Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing. allogeneic stem cell transplantation: a GITMO study. Haematologica. 2010;95:476–484. doi:10.3324/haematol.2009.011429
  • Wermke M, Eckoldt J, Götze KS, et al. Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial. Lancet Haematol. 2018;5:e201–e210. doi:10.1016/S2352-3026(18)30036-X
  • Petzer V, Wermke M, Tymoszuk P, et al. Enhanced labile plasma iron in hematopoietic stem cell transplanted patients promotes Aspergillus outgrowth. Blood Adv. 2019;3(11):1695–1700. doi:10.1182/bloodadvances.2019000043
  • Isidori A, Loscocco F, Visani G, et al. Iron toxicity and chelation therapy in hematopoietic stem cell transplant. Transpl Cell Ther. 2021;27:371379. doi:10.1016/j.jtct.2020.11.007
  • Cremers EMP, de Witte T, de Wreede L, et al. A prospective non interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation. Leuk Lymphoma. 2019;60:2404–2414. doi:10.1080/10428194.2019.1594215
  • Mahesh S, Yelena Ginzburg AV. Iron overload in myelodysplastic syndromes. Leuk Lymphoma. 2008;49:427–438. doi:10.1080/10428190701843221
  • Stumpf JL. Deferasirox. Am J Health Syst Pharm. 2007;64(6):606–616. doi:10.2146/ajhp060405
  • Vanorden HE, Hagemann TM. Deferasirox – an oral agent for chronic iron overload. Ann Pharmacother. 2006;40(6):1110–1117. doi:10.1345/aph.1G566
  • Shashaty G, Frankewich R, Chakraborti T, et al. Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis. Oncology. 2006;20(14):1799–1806.
  • Barton JC. Chelation therapy for iron overload. Curr Gastroenterol Rep. 2007;9(1):74–82. doi:10.1007/s11894-008-0024-9
  • Piga A, Galanello R, Forni GL, et al. Randomized Phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica. 2006;91(7):873–880.
  • Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2003;361(9369):1597–1602. doi:10.1016/S0140-6736(03)13309-0
  • Cappellini MD, Cohen A, Piga A, et al. A Phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood. 2006;107(9):3455–3462. doi:10.1182/blood-2005-08-3430
  • Pennell DJ, Porter JB, Cappellini MD, et al. Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major. Haematologica. 2012;97(6):842–848. doi:10.3324/haematol.2011.049957
  • Porter JB. Deferasirox: an effective once-daily orally active iron chelator. Drugs Today. 2006;42(10):623–637. doi:10.1358/dot.2006.42.10.1009901
  • Killick SB. Iron chelation therapy in low risk myelodysplastic syndrome. Br J Haematol. 2017;177:375–387. PMID: 28300275. doi:10.1111/bjh.14602
  • Lucijanic M, Lovrinov M, Skelin M. Iron chelation in transfusion-dependent patients with low- to intermediate-1-risk myelodysplastic syndromes. Ann Intern Med. 2020;173(7):595. doi:10.7326/L20-1055
  • Leitch HA, Parmar A, Wells RA, et al. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis. Br J Haematol. 2017;179:83–97. doi:10.1111/bjh.14825
  • Remacha AF, Arrizabalaga B, Villegas A, et al. Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications. Ann Hematol. 2015;94:779–787. doi:10.1007/s00277-014-2274-y
  • Malcovati L, Della Porta MG, Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica. 2006;91:1588–1590.
  • Lyons RM, Marek BJ, Paley C, et al. Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry. Leuk Res. 2014;38:149–154. doi:10.1016/j.leukres.2013.11.004
  • Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419–425.
  • Gattermann N, Finelli C, Porta MD, et al. Deferasirox in iron overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study. Leuk Res. 2010;34:1143–1150. doi:10.1016/j.leukres.2010.03.009
  • Angelucci E, Santini V, Di Tucci AA, et al. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial). Eur J Haematol. 2014;92:527–536. doi:10.1111/ejh.12300
  • Nolte F, Hochsmann B, Giagounidis A, et al. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload. Ann Hematol. 2013;92:191–198. doi:10.1007/s00277-012-1594-z
  • List AF, Baer MR, Steensma DP, et al. Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. J Clin Oncol. 2012;30:2134–2139. doi:10.1200/JCO.2010.34.1222
  • Maurillo L, Breccia M, Buccisano F, et al. Deferasirox chelation therapy in patients with transfusion-dependent MDS: a ‘realworld’ report from two regional Italian registries: gruppo Romano Mielodisplasie and Registro Basilicata. Eur J Haematol. 2015;95:52–56. doi:10.1111/ejh.12476
  • Breccia M, Fisinger P, Loglisci G, et al. Deferasirox treatment for myelodysplastic syndromes: “real-life” efficacy and safety in a single-institution patient population. Ann Haematol. 2012;91:1345–1349. doi:10.1007/s00277-012-1481-7
  • Gattermann N, Jarish A, Shlag R, et al. Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies Extend and EXJjange. Eur J Haematol. 2012;88(3):260–268. doi:10.1111/j.1600-0609.2011.01726.x
  • Rachmilewitz E, Merkel D, Ghoti H, et al. Improvement of oxidative stress parameters in MDS patients with iron overload treated with deferasirox. Blood. 2008;112(11):A924–A925. doi:10.1182/blood.V112.11.2675.2675
  • Chan LSA, Buckstein R, Reis MD, et al. Iron overload and haematopoiesis in MDS: does blood transfusion promote progression to AML? Blood. 2008;112(11):928a. doi:10.1182/blood.V112.11.2685.2685
  • List AF, Baer MR, Steensma D, et al. Deferasirox (ICL670); Exjade) reduces serum ferritin (SF) and labile plasma iron (LPI) in patients with myelodysplastic syndromes (MDS). Blood. 2008;112(11):523a.
  • Guzman M, Neering SJ, Upchurch D, et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood. 2001;98(8):2301–2307. doi:10.1182/blood.V98.8.2301
  • Carvalho G, Coquelle A, Vozenin MC, et al. NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood. 2006;107(3):1156–1165. doi:10.1182/blood-2005-05-1989
  • Messa E, Carturan S, Maffè C, et al. Deferasirox is a powerful NF-κB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica. 2010;95(8):1308–1316. doi:10.3324/haematol.2009.016824